Pipeline Review of Systemic Sclerosis - H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.


The latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2020, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 17, 11, 32 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Systemic Sclerosis (Scleroderma) - Overview
  • Systemic Sclerosis (Scleroderma) - Therapeutics Development
  • Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
  • Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
  • Systemic Sclerosis (Scleroderma) - Drug Profiles
  • Systemic Sclerosis (Scleroderma) - Dormant Projects
  • Systemic Sclerosis (Scleroderma) - Discontinued Products
  • Systemic Sclerosis (Scleroderma) - Product Development Milestones
  • Appendix

Companies Mentioned

  • Accuitis Pharmaceuticals Inc
  • AKL Research and Development Ltd
  • Allysta Pharmaceuticals Inc
  • Amgen Inc
  • AnaMar AB
  • Anima Biotech Inc
  • arGentis Pharmaceuticals LLC
  • Aryogen Pharmed Co
  • AstraZeneca Plc
  • Atlantic Healthcare Plc
  • Biogen Inc
  • Biomendics LLC
  • Blade Therapeutics Inc
  • BriaCell Therapeutics Corp
  • Bristol-Myers Squibb Co
  • Cantargia AB
  • Capella Bioscience Ltd
  • Castle Creek Pharmaceuticals LLC
  • ChemomAb Ltd
  • Civi Biopharma Inc
  • Cleveland Diabetes Care Inc
  • Corbus Pharmaceuticals Inc
  • CSL Ltd
  • Cumberland Pharmaceuticals Inc
  • Cureveda LLC
  • D&D Pharmatech Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Emerald Health Sciences Inc
  • Ergon Pharmaceuticals LLC
  • FBM Therapeutics LLC
  • Forbius
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • GenKyoTex SA
  • Gesynta Pharma AB
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GNI Group Ltd
  • H. Lundbeck AS
  • iBio Inc
  • Ichnos Sciences Inc
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Leadiant Biosciences Inc
  • Liminal BioSciences Inc
  • Link Genomics Inc
  • MDI Therapeutics Inc
  • medac GmbH
  • Opsidio LLC
  • Panorama Research Inc
  • Patagonia Pharmaceuticals LLC
  • PDX Pharmaceuticals LLC
  • Peptinov SAS
  • Pfizer Inc
  • PharmAkea Therapeutics Inc
  • Resolys Bio Inc
  • Ribomic Inc
  • Riptide Bioscience Inc
  • Samumed LLC
  • Sanofi
  • Seattle Genetics Inc
  • Signablok Inc
  • Stemline Therapeutics Inc
  • StemMed Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tvardi Therapeutics Inc
  • Unity Biotechnology Inc
  • Vicore Pharma AB
  • Viela Bio Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rje3y0


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900